Stock Scorecard



Stock Summary for Precigen Inc (PGEN) - $4.24 as of 2/6/2026 11:34:22 AM EST

Total Score

3 out of 30

Safety Score

31 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PGEN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PGEN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PGEN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PGEN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PGEN (31 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 2
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for PGEN

Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy 1/30/2026 11:30:00 PM
Institutional Investors May Overlook Precigen, Inc.'s (NASDAQ:PGEN) Recent US$110m Market Cap Drop as Long-term Gains Remain Positive 1/30/2026 8:22:00 PM
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th 1/30/2026 12:32:00 AM
Bringing a Breakthrough Rare Disease Product to Patients: Q&A with Helen Sabzevari 1/28/2026 10:59:00 AM
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Becomes Preferred First Line RRP Treatment 1/24/2026 6:58:00 PM
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis 1/24/2026 5:29:00 PM
Zacks Research Downgrades Precigen (NASDAQ:PGEN) to Strong Sell 1/24/2026 11:57:00 AM
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next 1/21/2026 8:27:00 PM
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next 1/21/2026 4:57:00 PM
Patient Capital Management LLC Grows Stake in Precigen, Inc. $PGEN 1/21/2026 12:57:00 PM

Financial Details for PGEN

Company Overview

Ticker PGEN
Company Name Precigen Inc
Country USA
Description Precigen Inc (PGEN), headquartered in Germantown, Maryland, is at the forefront of biotechnology, specializing in next-generation cell and gene therapies aimed primarily at treating cancer and autoimmune conditions. Leveraging its proprietary technologies, the company is dedicated to enhancing immune responses and improving clinical outcomes for patients with significant unmet medical needs. With a promising pipeline of innovative treatments, Precigen is strategically positioned to make a substantial impact in the biologics arena, underscoring its commitment to scientific excellence and patient-centered therapeutic advancements.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 3/18/2026

Stock Price History

Last Day Price 4.24
Price 4 Years Ago 1.52
Last Day Price Updated 2/6/2026 11:34:22 AM EST
Last Day Volume 3,736,702
Average Daily Volume 3,887,857
52-Week High 5.22
52-Week Low 1.11
Last Price to 52 Week Low 281.98%

Valuation Measures

Trailing PE N/A
Industry PE 26.47
Sector PE 152.45
5-Year Average PE -4.48
Free Cash Flow Ratio 106.00
Industry Free Cash Flow Ratio 13.67
Sector Free Cash Flow Ratio 27.03
Current Ratio Most Recent Quarter 4.04
Total Cash Per Share 0.04
Book Value Per Share Most Recent Quarter -0.12
Price to Book Ratio 36.34
Industry Price to Book Ratio 48.56
Sector Price to Book Ratio 51.46
Price to Sales Ratio Twelve Trailing Months 240.59
Industry Price to Sales Ratio Twelve Trailing Months 9.10
Sector Price to Sales Ratio Twelve Trailing Months 13.39
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 352,910,000
Market Capitalization 1,496,338,400
Institutional Ownership 63.49%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 1
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -31.63%
Reported EPS 12 Trailing Months -0.41
Reported EPS Past Year -1.33
Reported EPS Prior Year -0.32
Net Income Twelve Trailing Months -246,866,000
Net Income Past Year -126,235,000
Net Income Prior Year -95,904,000
Quarterly Revenue Growth YOY 19.40%
5-Year Revenue Growth -34.27%
Operating Margin Twelve Trailing Months -3,254.00%

Balance Sheet

Total Cash Most Recent Quarter 14,322,000
Total Cash Past Year 29,517,000
Total Cash Prior Year 7,578,000
Net Cash Position Most Recent Quarter -78,568,000
Net Cash Position Past Year -13,702,000
Long Term Debt Past Year 43,219,000
Long Term Debt Prior Year 43,219,000
Total Debt Most Recent Quarter 92,890,000
Equity to Debt Ratio Past Year 0.47
Equity to Debt Ratio Most Recent Quarter 0.31
Total Stockholder Equity Past Year 38,513,000
Total Stockholder Equity Prior Year 118,498,000
Total Stockholder Equity Most Recent Quarter 41,868,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -75,619,000
Free Cash Flow Per Share Twelve Trailing Months -0.21
Free Cash Flow Past Year -76,757,000
Free Cash Flow Prior Year -68,466,000

Options

Put/Call Ratio 0.02
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.15
MACD Signal 0.14
20-Day Bollinger Lower Band 3.14
20-Day Bollinger Middle Band 4.08
20-Day Bollinger Upper Band 5.03
Beta 1.16
RSI 56.38
50-Day SMA 2.81
150-Day SMA 1.78
200-Day SMA 0.00

System

Modified 2/7/2026 5:53:06 AM EST